About Us

OVERVIEW

Recida Therapeutics, Inc. is a privately-held biopharmaceutical company focused on the development of novel-class antibiotics to address the expanding problem of multi-drug resistant gram-negative bacteria. Treatment of infections caused by resistant gram-negative bacteria — especially Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii– is recognized as an unmet medical need by the global infectious diseases community. No new class of anti-gram-negative agents has been successfully developed in fifty years. There is a clear unmet medical need for antibiotics with a new mechanism of action against these potentially deadly pathogens.
Recida’s lead product, RC-01, is a novel LpxC inhibitor exhibiting potent in vitro and in vivo antibacterial activity against drug-resistant gram-negative bacteria, including many that are highly resistant to currently available antibiotics. RC-01 has demonstrated a favorable preclinical pharmacokinetic and efficacy profile as well as an excellent preclinical safety profile in animals. In addition, RC-01 has unique antibacterial features that make it highly differentiated from currently marketed drugs. RC-01 is currently under development as an intravenous formulation enabling its use in the hospital to treat serious infections caused by target organisms. A Phase 1 study is planned to evaluate the safety and pharmacokinetic profiles of RC-01 Injection in humans.

 

 

HISTORY

Recida was founded in 2017 by Drs. James Ge, Vernon Jiang, George H. Talbot and Paul Eckburg, along with Tachi Yamada and David Socks, Venture Partners of Frazier Healthcare Partners. Shortly thereafter, Recida acquired the global development and commercial rights to RC-01 (T-1228) from Toyama Chemical Corp (a subsidiary of Fujifilm Holdings Corporation). Recida’s management team has a track record of recent successes in the clinical development of antibacterial agents, including gemifloxacin, doripenem, ceftaroline, ceftolozane/tazobactam, and dalbavancin. In June 2018, the Company raised a $8.25 million Series A round from Frazier Healthcare Partners. The Company also entered into a partnership with MicuRx Pharmaceuticals, Inc. for development and commercialization in the Greater China region. Recida has been awarded a $3.0 M grant from CARB-X to support the preparation of the IND and Phase 1 clinical trial.

Management Team

James (Yigong) Ge, Ph.D., M.D.
President, Chief Executive Officer, Acting Chief Scientific Officer

Dr. Ge is Co-Founder, President and Chief Executive Officer of Recida Therapeutics, Inc. Dr. Ge is a biotech entrepreneur with an established track record of successful antibacterial drug development. Over the last two decades, he participated in the development of many different classes of antibiotics, including four marketed products. He was involved in creating multiple biotech companies, including Cerexa, Calixa Pharmaceuticals, Kalidex Pharmaceuticals, Nexcida Therapeutics and Recida Therapeutics. Prior to founding Recida, Dr. Ge served as the Founder, President and Chief Scientific Officer of Nexcida Therapeutics, Inc, a company focused on licensing and development of new anti-infectives. He played a leadership role at Calixa Pharmaceuticals, heading the team that successfully executed the ceftolozane/ tazobactam (ZerbaxaÒ) clinical development program, which led to its acquisition by Cubist Pharmaceuticals Inc. He was also a senior executive at MicuRx Pharmaceuticals, ALEAD Pharmaceuticals, Forest Laboratories, Peninsula Pharmaceuticals and Genesoft.  Dr. Ge played a key strategic role in two other acquisitions: Peninsula Pharmaceuticals (by Johnson and Johnson) and Cerexa (Forest Laboratories). Prior to his position at Peninsula, Dr. Ge served in various roles at Magainin Pharmaceuticals Inc. and SmithKline Beecham Pharmaceuticals. Dr. Ge received a Ph.D. in medical microbiology at West Virginia University, Morgantown. Dr. Ge also received an M.D. at The Second Military Medical University of Shanghai, China.

 

Paul Eckburg, M.D.
Acting Vice President of Clinical Development

Dr. Eckburg is the Acting Vice President of Clinical Development at Recida Therapeutics. Dr. Eckburg has over 19 years of experience in anti-infective drug development, including prior consultation for Peninsula Pharmaceuticals (doripenem), Versicor (anidulafungin), Allergan (ceftaroline-avibactam), Mpex (inhaled levofloxacin), Rempex (meropenem-vaborbactam, oritavancin), MicuRx (contezolid), Achaogen (plazomicin), Wockhardt (nafithromycin, cefepime-zidebactam), Paratek (omadacycline), and Spero (tebipenem, polymyxin potentiators), including as Acting CMO for Zavante (fosfomycin), Geom (siderophore cephalosporin), and Utility (pivmecillinam, mecillinam). He was also employed as Senior Director of Clinical Development at Cerexa (a wholly-owned subsidiary of Forest Laboratories), where he was responsible for the ceftaroline clinical development program. Dr. Eckburg completed his Internal Medicine residency and Infectious Diseases fellowship at Stanford University School of Medicine, and remains active at Stanford as Adjunct Clinical Assistant Professor in Infectious Diseases & Geographic Medicine.

 

Asha Rajagopal
Acting Chief Financial Officer

Asha Rajagopal joined the Recida Therapeuticss management team as Acting CFO with 30 years of experience in public accounting and private industry, including work with small companies and large corporations. Her biopharmaceutical industry experience includes heading the finance function at Genesoft Pharmaceuticals, where she participated in directing the reverse merger with Oscient Pharmaceuticals (NASD:OSCI) in 2004. Ms. Rajagopal also held senior finance positions at Cygent, Cambridge Management Consulting, Abbott Laboratories and Price Waterhouse. Her expertise is small and large business finance and accounting processes, IPO support and accounting for merger and acquisitions. Ms. Rajagopal recently supported the IPO  of MyoKardia, Protagonist Therapeutics and Eidos Therapeutics. Ms. Rajagopal received her BSBA in Accounting from the University of Texas and is a licensed CPA in California.

 

Georgina Kilfoil
Acting Head of Clinical Operation and Portfolio Management

Georgina Kilfoil is the Acting Head of Clinical Operation and Portfolio Management at Recida Therapeutics. Georgina Kilfoil has almost thirty years of experience with a proven track record in building, growing, and financing life-science ventures with specific expertise in strategic drug development, operational project management, and clinical plan execution. Most recently, Ms. Kilfoil was Chief Development Officer at Benitec Biopharma. Over the past twenty years, Ms. Kilfoil has been involved with, and in some cases led the development behind, several marketed anti-infective such as doripenem (Doribax®), ceftolozane/tazobactam (Zerbaxa®), ceftaroline (Teflaro®), anidulafungin (Eraxis®). Ms Kilfoil is a certified Project Management Professional, has a Bachelor of Science Honours Degree in Pharmacology from the University of Bristol, United Kingdom, and a Master of Business Administration from the Australian Graduate School of Management, Sydney, Australia.

 

George H. Talbot, M.D, FACP, FIDSA
Senior Clinical Advisor

Dr. Talbot, an Infectious Diseases physician trained at the University of Pennsylvania Medical Center, began his pharmaceutical career in anti-infective drug development at Rhone-Poulenc Rorer, subsequently Aventis. He founded his consultancy firm, Talbot Advisors LLC, in 2000. Dr. Talbot has contributed to the clinical development programs of numerous antibiotics.  After consulting to Peninsula Pharmaceuticals, Inc. (purchased by Johnson and Johnson), Dr. Talbot served as Executive Vice President/ Chief Medical Officer of Cerexa, Inc., which was acquired by Forest Laboratories in 2007. He subsequently was Senior Advisor and Chairman of the Scientific Advisory Board of Calixa, Inc., which Cubist Pharmaceuticals purchased in 2009. He chaired the Scientific Advisory Boards of Durata Therapeutics, Inc. (acquired by Actavis plc in 2014) and Kalidex, Inc., companies for which he also was Senior Advisor, and was a member of the Scientific Advisory Board of Actelion Pharmaceuticals.  He has worked with Nabriva Therapeutics, plc since its founding and has been a member of its Supervisory Board since 2009. A Fellow of the IDSA and a member of the ASM, Dr. Talbot has been elected a Fellow of the American College of Physicians. He was a founding member of IDSA’s Antimicrobial Availability Task Force (“Bad Bugs, No Drugs”), currently sits on IDSA’s Antimicrobial Resistance Committee, was a committee member of the CLSI (previously NCCLS), and is past co-chair of the ABSSSI/CABP and HABP/VABP Clinical Trial Endpoint Development Project Teams at the Foundation of the National Institutes of Health Biomarkers Consortium. He has co-authored over 100 publications in peer-reviewed scientific journals.

 

Vernon Jiang, Ph.D.
Senior Advisor, CMC

Dr. Jiang is a co-founder of Recida Therapeutics and Senior CMC Adviser . Dr. Jiang has over 24 years of experience in drug formulation research, process development, and manufacturing from the research stage to commercialization. He held senior positions at multiple antibiotic companies,  Genesoft Pharmaceuticals, Cerexa/Forest Laboratories, Calixa Therapeutics/Cubist Pharmaceuticals, Kalidex Pharmaceuticals, and Nexida Therapeutics.  Most recently he has held senior positions in pharmaceutical development at Aldea Pharmaceuticals,  and K-Gen, Inc./Ferro Therapeutics. He played a key role in developing Teflaro® (ceftaroline fosamil) and Zerbaxa®, with multiple patent inventions, as well as Dalvance® (Dalbavancin). Dr. Jiang received a Ph.D. in chemistry from Duke University.

Board Members

David Socks, Executive Chairman

Mr. Socks is Executive Chairman and co-founder of Recida Therapeutics.  He is also a Venture Partner with Frazier Healthcare Partners where he served as founding CEO of Outpost Medicine, Scout Bio, and Nexcida Therapeutics. Prior to joining Frazier, Mr. Socks co-founded Incline Therapeutics as its President and COO until its sale to The Medicines Company for up to $390 million. He also co-founded Cadence Pharmaceuticals (NASDAQ: CADX) and served as its Senior Vice President, Corporate Development and Strategy. Cadence received FDA approval for OFIRMEV (acetaminophen injection) and was acquired by Mallinckrodt for $1.3 billion. Previously, Mr. Socks was a Venture Partner at Windamere Venture Partners, where he co-founded companies including Somaxon Pharmaceuticals (NASDAQ: SOMX; acquired by Pernix Therapeutics) and Verus Pharmaceuticals (acquired by AstraZeneca and Shionogi/Sciele). Previously, he worked at Neurocrine Biosciences, EFO Holdings, and Kaiser Associates. Mr. Socks holds a B.S. from Georgetown University and an M.B.A. from Stanford University.

 

Patrick Heron

Mr. Heron is a member of the Board of Directors of Recida Therapeutics. He is Managing General Partner of Frazier Healthcare Partners, a dedicated life sciences investment firm, co-leads Frazier’s Life Sciences team, and invests across the spectrum of therapeutics opportunities, from early-stage clinical development companies to commercial-stage pharmaceutical companies. Throughout his 13 years as a General Partner, Mr. Heron has led or co-led investments across nearly 20 companies, including many successful anti-infectives focused companies. Prior to joining Frazier, he helped develop McKinsey’s West Coast biotechnology practice, where he led projects involving mergers and acquisitions, product launches, sales force optimization, corporate partnering, and research prioritization. Mr. Heron received his M.B.A. from Harvard Business School. He also holds a B.A. from the University of North Carolina at Chapel Hill, where he was elected to Phi Beta Kappa and was selected as a Morehead Scholar.

 

James (Yigong) Ge, Ph.D., M.D. 

Dr. Ge is Co-Founder, President and Chief Executive Officer of Recida Therapeutics, Inc. Dr. Ge is a biotech entrepreneur with an established track record of successful antibacterial drug development. Over the last two decades, he participated in the development of many different classes of antibiotics, including four marketed products. He was involved in creating multiple biotech companies, including Cerexa, Calixa Pharmaceuticals, Kalidex Pharmaceuticals, Nexcida Therapeutics and Recida Therapeutics. Prior to founding Recida, Dr. Ge served as the Founder, President and Chief Scientific Officer of Nexcida Therapeutics, Inc, a company focused on licensing and development of new anti-infectives. He played a leadership role at Calixa Pharmaceuticals, heading the team that successfully executed the ceftolozane/ tazobactam (ZerbaxaÒ) clinical development program, which led to its acquisition by Cubist Pharmaceuticals Inc. He was also a senior executive at MicuRx Pharmaceuticals, ALEAD Pharmaceuticals, Forest Laboratories, Peninsula Pharmaceuticals and Genesoft.  Dr. Ge played a key strategic role in two other acquisitions: Peninsula Pharmaceuticals (by Johnson and Johnson) and Cerexa (Forest Laboratories). Prior to his position at Peninsula, Dr. Ge served in various roles at Magainin Pharmaceuticals Inc. and SmithKline Beecham Pharmaceuticals. Dr. Ge received a Ph.D. in medical microbiology at West Virginia University, Morgantown. Dr. Ge also received an M.D. at The Second Military Medical University of Shanghai, China.

 

Scientific Advisory Board

George H. Talbot, M.D, FIDSA (Chairperson)

Dr. Talbot, an Infectious Diseases physician trained at the University of Pennsylvania Medical Center, began his pharmaceutical career in anti-infective drug development at Rhone-Poulenc Rorer, subsequently Aventis. He founded his consultancy firm, Talbot Advisors LLC, in 2000. Dr. Talbot has contributed to the clinical development programs of numerous antibiotics.  After consulting to Peninsula Pharmaceuticals, Inc. (purchased by Johnson and Johnson), Dr. Talbot served as Executive Vice President/ Chief Medical Officer of Cerexa, Inc., which was acquired by Forest Laboratories in 2007. He subsequently was Senior Advisor and Chairman of the Scientific Advisory Board of Calixa, Inc., which Cubist Pharmaceuticals purchased in 2009. He chaired the Scientific Advisory Boards of Durata Therapeutics, Inc. (acquired by Actavis, plc in 2014) and Kalidex, Inc., companies for which he also was Senior Advisor, and was a member of the Scientific Advisory Board of Actelion Pharmaceuticals.  He has worked with Nabriva Therapeutics plc since its founding and has been a member of its Supervisory Board since 2009. A Fellow of the IDSA and a member of the ASM, Dr. Talbot has been elected a Fellow of the American College of Physicians.  He was a founding member of IDSA’s Antimicrobial Availability Task Force (“Bad Bugs, No Drugs”), currently sits on IDSA’s Antimicrobial Resistance Committee, was a committee member of the CLSI (previously NCCLS), and is past co-chair of the ABSSSI/CABP and HABP/VABP Clinical Trial Endpoint Development Project Teams at the Foundation of the National Institutes of Health Biomarkers Consortium. He has co-authored over 100 publications in peer-reviewed scientific journals.

 

Antonio Oliver, Ph.D.

Antonio Oliver, a Doctor in Pharmacy (Complutense University of Madrid, 2002) and Specialist in Clinical Microbiology (Hospital Ramón y Cajal, Madrid, 2001), has worked since 2002 as a Clinical Microbiologist in the Department of Microbiology of Hospital Son Espases (formerly Hospital Son Dureta) in Palma de Mallorca. In 2003 Dr. Oliver was appointed an Associate Professor of Microbiology in the University of the Balearic Islands and is the Principal Investigator of the Antimicrobial Resistance and Pathogenicity of Bacterial Infections Group of the Health Research Institute of the Balearic Islands. Dr. Oliver is a member of the Scientific Committee of the Spanish Network for Research in Infectious Diseases and an ESCMID fellow. His main research interest includes the investigation of the mechanisms of adaptation and antimicrobial resistance in bacterial pathogens, with a particular focus on Pseudomonas aeruginosa infections and the development of the novel strategies to combat them. Dr. Oliver has published over 200 manuscripts within this field in peer-reviewed journals.

 

Yohei Doi, M.D., Ph.D.

Dr. Yohei Doi is Associate Professor of Medicine and Director of the Center for Innovative Antimicrobial Therapy at the University of Pittsburgh. He was graduated from Nagoya University School of Medicine in Nagoya, Japan. After training in internal medicine and basic research on characterization of novel antimicrobial resistance mechanisms in Gram-negative pathogens, he moved to the United States to pursue further clinical training, completing a residency in categorical medicine at St. Luke’s Roosevelt Hospital Center, then an infectious diseases fellowship at the University of Pittsburgh, where he also received training in clinical and translational research. His research focuses on mechanisms of antimicrobial resistance in highly drug-resistant gram-negative bacterial pathogens and devising ways to overcome them. He has authored over 150 articles in peer-reviewed journals and mentored over 30 students and trainees in his laboratory. He currently chairs the gram-negative committee of the Antibacterial Resistance Leadership Group.

 

Mark H. Wilcox, M.D.

Professor Mark H. Wilcox, MD is a Consultant / Head of Microbiology Research & Development / and Infection Lead of the Leeds NIHR MIC at Leeds Teaching Hospitals; Professor of Medical Microbiology, at the University of Leeds; Lead on C. difficile infection (CDI) for Public Health England (PHE); and Medical Advisor to the National Infection Prevention & Control Lead at NHS Improvement (national target to reduce gram-negative bloodstream infections). He has formerly been the Director of Infection Prevention (4 years), Infection Control Doctor (8 years), Clinical Director of Pathology (6 years) at LTHT and Head of Microbiology (15 years). Professor Wilcox chairs PHE’s Rapid Review Panel (reviews the utility of infection prevention & control products for the NHS), and is Deputy Chair of the UK Department of Health’s Antimicrobial Resistance and Healthcare-Associated Infection Committee.  He is a member of the Medical Research Council’s Infections and Immunity Board.  He co-leads the EU Innovative Medicines Initiative’s COMBACTE-CDI consortium.  Professor Wilcox is an advisor to UK EPIC/NICE projects, the Wellcome Trust and the CARB-X panel on novel antimicrobials, European Centre for Disease Control, and a member of UK/European/US working groups on CDI.  He has provided clinical advice to FDA/EMA submissions for the approval of multiple novel antimicrobial agents, 1998-2018.  He heads a Healthcare-Associated Infection research team at the University of Leeds, has authored >480 papers, and is co-editor of Antimicrobial Chemotherapy (Eds, 2007/12/15).

 

Paul G. Ambrose, Pharm.D.

Paul G. Ambrose is President of the Institute for Clinical Pharmacodynamics (ICPD), Latham, New York, USA. He also has been an Honorary Research Fellow in Infectious Diseases at the University of Oxford, Oxford, UK and Adjunct Associate Research Professor at the University at Buffalo, Buffalo, New York. Dr. Ambrose’s areas of scientific inquiry primarily involve anti-infective translational science, with the goal of improving patient care through the application of pharmacokinetic-pharmacodynamic (PK-PD) principles. Knowledge gained through the use of non-clinical (in vitro and animal) PK-PD infection models may be leveraged with human pharmacokinetic data in order to discriminate between potential dosing regimens and thereby increase the probability of positive clinical outcomes while minimizing the potential for drug-related toxicities. ICPD has successfully utilized this approach for support of regulatory decision-making and as support for susceptibility breakpoint determinations.  Dr. Ambrose has served as an Editor of Antimicrobial Agents Chemotherapy and an Editorial Board Member of the Journal of Infectious Disease Pharmacotherapy. He is the author of over 120 peer-reviewed scientific publications and approximately 500 scientific abstracts. Dr. Ambrose has served as an Editor for four textbooks, most notably the 1st and 2nd Editions of Antimicrobial Pharmacodynamics in Theory and Clinical Practice.

Investors

logo_frazier

Frazier Healthcare Partners

http://www.frazierhealthcare.com

Collaborations

logo_carbx

Partnerships

logo_micurx

MicuRx Pharmaceuticals, Inc.

http://www.micurx.com